Currently, there are 15 ADC drugs approved globally, among which 6 ADC drugs have been approved in China, namely Trastuzumab emtansine, Brentuximab vedotin, Trastuzumab deruxtecan, Vidofludimus, Gemtuzumab ozogamicin, and Sacituzumab govitecan. This article provides a brief summary based on the currently approved ADC drugs worldwide, the types of tumors they are suitable for, and how … Read more
1. Mechanism of ADC Action Antibody-drug conjugates (ADC) (Click to enter the database to search for global ADC drug information) enter the body, the antibody part binds to the targeted antigen on the surface of tumor cells, tumor cells will endocytose the ADC molecule. Among them, some can bind to Fc receptors in the endosome, … Read more
Antibody-drug conjugates (ADC), also known as “magic bullets,” use monoclonal antibodies (Antibody) to deliver small molecule drugs (Drug) directly to tumor cells expressing specific antigens through a linker (Conjugate). In recent years, ADC drugs have rewritten the treatment guidelines for blood cancers, breast cancer, ovarian cancer, and lung cancer, providing patients with significantly improved clinical … Read more
Antibody-drug conjugates (ADC) are formed by the coupling of specific targeting monoclonal antibodies and highly active cytotoxic drugs through linkers. With their unique pharmaceutical properties, ADC drugs exhibit strong anti-tumor activity in the field of cancer therapy, while also offering higher safety compared to traditional chemotherapy. In recent years, the development of ADC drugs in … Read more
*For reference only by medical professionals The latest review reports that ADC drug resistance is related to antigen expression, ADC processing, and payload efficacy. Antibody-drug conjugates (ADC) are formed by the conjugation of specific targeting monoclonal antibodies and highly active cytotoxic drugs via linkers. With their unique pharmacological properties, ADC drugs exhibit powerful anti-tumor activity … Read more
Compiled by: Oncology Information Source: Oncology Information Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with cytotoxic small molecule drugs, combining the targeting specificity of antibody drugs with the powerful lethality of cytotoxins. The aim is to overcome the issues of weak cytotoxicity of monoclonal antibodies and the high toxicity … Read more
After the era of chemotherapy, targeted therapy, and immunotherapy, the ADC (antibody-drug conjugate) drugs, which couple cytotoxic drugs with targeted monoclonal antibodies, have opened the era of the fourth ladder of tumor drug therapy with excellent results. They have now become a new class of drugs in tumor treatment that cannot be ignored both domestically … Read more
ADC In the era following chemotherapy, targeted therapy, and immunotherapy, ADC drugs, which combine cytotoxic drugs with targeted monoclonal antibodies, have opened a new era of fourth-line cancer treatment with exceptional results. They have become a significant class of new drugs in cancer treatment both domestically and internationally. So, what are ADC drugs (antibody-drug conjugates)? … Read more
Introduction Antibody-drug conjugates (ADCs) consist of antibodies, linkers, and cytotoxic payloads. Compared to traditional chemotherapy, ADCs target tumors with the promise of reducing systemic toxicity, providing a broader therapeutic window and a higher therapeutic index. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary … Read more
Introduction Antibody-Drug Conjugates (ADCs) are targeted therapies that consist of antibodies, linkers, and cytotoxic drugs, using monoclonal antibodies as carriers to efficiently deliver cytotoxic drugs to target tumor cells in a targeted manner, combining the powerful killing effect of traditional chemotherapy with the tumor-targeting capability of antibody drugs. An ideal ADC maintains stability in the … Read more